SSO 2017: Preclinical Trial Shows Intratumoral Vaccination Induces Antitumor Response in Pancreatic Cancer

Key Points

  • An antigen-expressing vaccine was administered directly to the pancreas in mouse models, as well as the booster at regular intervals on days 4 and 18. This was followed by resection of the primary pancreatic tumor on day 28.
  • Tumors of the vaccine-treated mice were smaller in size compared to controls, and they also displayed significant increases in immune populations that are associated with antitumor immunity.
  • Vaccinated mice also exhibited markedly prolonged survival compared to the controls.

Building on their previous research focusing on intratumoral vaccination for the most common form of pancreatic cancer, investigators from Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School have shown that in a mouse model of early-stage resected pancreatic cancer, intratumoral vaccination induces an antitumor response that results in a significant improvement in overall survival. Results of the work were presented as part of a poster presentation by Dudgeon et al at the 70th Annual Society of Surgical Oncology Cancer Symposium (Abstract PT187).

Earlier Findings

The group’s previous work focused on the investigational vaccine known as PANVAC, which contains gene additives that might stimulate a patient’s immune system to recognize and develop an immune response to the disease. In a phase I clinical trial, patients with pancreatic ductal adenocarcinoma were treated with PANVAC through direct tumor injection via endoscopic ultrasound, which was followed with a PANVAC booster. In that trial, the median overall survival of patients who received the vaccine was not significantly greater than that of patients with the same stage of disease treated with standard therapy.

Eight vaccine recipients in the phase I trial who did not have metastatic disease when they began the trial ended up succumbing to the disease following progression of the primary tumor in the pancreas, which is unusual, said investigators. Because of that response, the researchers hypothesized that perhaps the vaccine can induce an immune response that protects against the development of metastatic disease, but does not affect an already-present tumor. They aimed to further explore whether intratumoral vaccination would have a better chance at improving survival if it were applied to patients with early-stage disease who could undergo removal of their pancreatic tumor following vaccination.

Animal Study

In order to test this theory in a human clinical trial, researchers first needed to see if they could produce this result in an animal model. Since no mouse models of early-stage resectable pancreatic cancer exist, the laboratory of Darren Carpizo, MD, PhD, surgical oncologist at Rutgers Cancer Institute and senior investigator of the work, had to first develop one. The Carpizo laboratory then collaborated with the laboratory of Rutgers Cancer Institute researcher and Associate Director for Education and Training Edmund C. Lattime, PhD, to conduct the vaccination experiments.

An antigen-expressing vaccine was administered directly to the pancreas in mouse models, as well as the booster at regular intervals on days 4 and 18. This was followed by resection of the primary pancreatic tumor on day 28.

The investigators found that the tumors of the vaccine-treated mice were smaller in size compared to controls, and they also displayed significant increases in immune populations that are associated with antitumor immunity. They also found that the vaccinated mice exhibited markedly prolonged survival compared to controls, suggesting that the vaccine allowed their immune system to protect them from acquiring metastatic disease.

“These findings will provide the necessary preclinical data to test a vaccine like PANVAC in humans with resectable pancreatic cancer. Such a human trial has never been done before,” said Dr. Carpizo, also the Director of the Hepatobiliary Oncology Program at Rutgers Cancer Institute and an Associate Professor of Surgery and Pharmacology at Rutgers Robert Wood Johnson Medical School.

The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.


Advertisement

Advertisement



Advertisement